TB-500

TB-500 significantly increased maximum load to failure compared to controls (p < 0.05), while BPC-157 showed a non-significant trend.; TB-500 significantly reduced total Bonar and Movin scores, and BPC+TB reduced Movin scores, indicating improved tendon architecture and reduced degeneration.; Sirius red analysis revealed increased type I collagen organization and altered type III distribution in treatment groups, especially TB-500, suggesting matrix maturation.; Combined BPC-157 and TB-500 did not provide additional benefits over either agent alone.

TB-300 improved body weight by 4.6% and FCR by 5.2%.; SB-500 significantly reduced litter Clostridia and aerobic bacteria counts.; TB-300 and SB-500 enhanced duodenal villi height and crypt-villus ratio.; All butyrate treatments increased serum total proteins and digestive enzymes.

Ac-LK was the primary metabolite with highest concentration in rats at 0-6 h intervals.; Ac-LKK was a long-term metabolite detected up to 72 hours.; No cytotoxicity was observed for TB-500 or its metabolites.; Ac-LKKTE exhibited significant wound healing activity compared to the control.

Kerosene use was consistently associated with TB incidence (AOR 2.62, 95% CI 1.95-3.54).; A subset model with kerosene use, ventilation, workplace, and gender was deemed acceptable for estimating TB probability.; A 50% reduction in kerosene use could reduce TB probability by 13.29% in respiratory patients.; Recommendation was to replace kerosene with clean fuels like LPG or natural gas and promote rural electrification.

Peptide adsorption to surfaces is a concern for low-concentration measurements (ng/mL-pg/mL).; Expensive low-bind consumables are not always advantageous for recovery.; Optimal consumable choice depends on the peptide's physicochemical features.

Dilution with 200 mM phosphate buffer provides good buffering capacity without affecting peptide recoveries.; Microelution SPE showed comparable recovery, linearity, and reproducibility to cartridge SPE.; Limits of detection increased for 5 out of 17 peptides with microelution due to lower pre-concentration factor.; Microelution plates reduce solvent consumption and allow simultaneous processing of up to 96 samples.

Several metabolites were detected for each peptide after incubation with human liver microsomes, S9 fraction, and serum.; No significant differences were observed between in vitro models from different organs (liver vs. kidney).; Deamidation was not observed in any model and required evaluation with α-chymotrypsin.; In vitro models are useful tools for detecting peptidic metabolic markers in biological fluids.

Limits of detection for all seven peptides were less than 50 pg/mL.; Method validated for specificity, precision, and recovery.; Detected N-acetylated LKKTETQ and its metabolite in plasma after TB-500 administration.; First identification of in vitro metabolites for all studied peptides except TB-500 in horses.

What is TB-500?

**Mechanism of Action** TB-500 (Thymosin Beta-4 fragment) is a synthetic peptide corresponding to the actin-binding domain (Ac-SDKP region) of the endogenous protein thymosin β4. It primarily functions by sequestering monomeric actin (G-actin), thereby regulating cytoskeletal dynamics and promoting cell migration. This

How does TB-500 work?

Synthetic version of the actin-binding region of thymosin β4; promotes cell migration, angiogenesis, and wound repair.

What is the research status of TB-500?

TB-500 is currently classified as preclinical, with 26 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of TB-500?

TB-500 has a molecular weight of approximately 889 g/mol (formula C38H68N10O14).